CRISPR screening reveals targets to reprogram long-lived effector CD8+ T cells for cancer therapy. [ATAC-Seq]

CD8+ T cells can be reprogrammed for better persistence and robust effector function in TME. By performing an in vivo pooled CRISPR-Cas9 mutagenesis screening of metabolism-associated factors, we identify Regnase-1 as a major negative regulator of antitumor responses, whose deficiency results in drastically increased CD8+ T cell accumulation in tumors Overall design: We used Co-Transfer system ATAC seq to compare chromatin accessibility profiles of Regnase1-null and WT CD8+ T cells population from tumors.